Actinogen Medical (ASX:ACW) recently announced results from its XanaCIDD Phase 2a trials, which demonstrated the drug’s significant clinical and statistical benefits over a placebo in treating depression.
CEO Steve Gourlay emphasised its potential as a safer and more effective alternative to current antidepressants, particularly for patients with milder forms of depression.
The trial results showed early and lasting improvements in depressive symptoms, and it’s unique mechanism of reducing chronic stress by lowering cortisol levels which sets it apart from other treatments.
Actinogen Medical is now completing the trial analysis, engaging with potential strategic partners, and continuing their Alzheimer’s research in a phase two B trial, aiming to show that Xanamem can also slow the progression of Alzheimer’s disease.
Disclaimer: The Market Online has a commercial relationship with Actinogen.